News & Publications
|Presentations
November, 2024
OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AML
BusinessWire
November, 2023
Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment
Thomas Pabst, et al. Lancet Haematol
April, 2023
Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction
Lanqi Gong et al. Nature Communications
March, 2023
OncoVerity, Inc. Announces Exclusive Worldwide Licensing Rights to Cusatuzumab and Appoints Max Colao as Chief Executive Officer
Businesswire
January, 2023
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
Thomas Pabst et al. Haematologica
August, 2021
An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma
Astrid De Meulenaere et al. Clinical and Translational Science
September, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
Carsten Riether et al. Nature Medicine
December, 2016
CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia
Carsten Riether et al. The Journal of Experimental Medicine